A comparison of techniques in electro-convulsive therapy.
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
M Valentine
Publications and source records attributed to M Valentine.
Phenothiazines and eye complications.
Explore the source record for details and available documents.
Adult↗
Tri-Nasal triamcinolone acetonide nasal spray 200 and 400 micrograms qd versus placebo and Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd in patients suffering from seasonal allergic rhinitis during the grass season.
Tri-Nasal Nasal Spray is an investigational solution of triamcinolone acetonide (TAA) currently being evaluated as a treatment for allergic rhinitis. The safety and efficacy of 200 and 400 micrograms once daily doses of Tri-Nasal Nasal Spray, an active control (440 micrograms once daily of Nasacort Nasal aerosol), and Tri-Nasal Nasal Spray placebo were compared over a 2-week treatment period in a double-blind (the Nasacort treatment was not blinded), parallel design trial. A total of 377 adult patients in 13 centers were enrolled during the grass pollen season. The primary efficacy variable was the weekly average of the SSI (Symptom Severity Index), the sum of daily nasal congestion, rhinorrhea, and sneezing severity scores from the patient diary. A total of 355 patients completed the study. All active treatments were significantly more effective than placebo in relieving nasal symptoms at each treatment week. The 400 micrograms Tri-Nasal Nasal Spray and Nasacort treatments had a rapid onset of action, demonstrating significant improvement in the SSI versus placebo by the second day of treatment. Results for the individual nasal symptoms and other secondary efficacy measures paralleled those of the primary efficacy variables. Tri-Nasal Nasal Spray and Nasacort were comparable in safety, and in treating the nonocular symptoms of seasonal allergic rhinitis.
Administration, Intranasal↗
Assignment of the human progression associated protein (PAP) to chromosome 12p12.3.
Analysis of mammary carcinoma cell lines MCF-7 and MCF-7ADR by differential display resulted in the identification of a new putative transmembrane protein, PAP (Progression Associated Protein). Cell lines MCF-7 and MCF-7ADR represent a model system for the identification of genes involved in the clinical progression of human breast cancer. According to the functions assigned to some members of its family, PAP might be involved in cell cycle regulation and cell-cell interactions. Here we describe the chromosomal localization of the PAP gene by the use of fluorescence in situ hybridization (FISH) with two different genomic DNA probes, derived from the 3'-untranslated and the 5'-translated region of the PAP cDNA sequence. The results of the chromosomal localization experiments indicate that the PAP gene is located on human chromosome 12p12.3.
Breast Neoplasms↗